Early Secreted Antigen ESAT-6 of Mycobacterium tuberculosis Promotes Protective T Helper 17 Cell Responses in a Toll-Like Receptor-2-dependent Manner

Despite its relatively poor efficacy, Bacillus Calmette-Guérin (BCG) has been used as a tuberculosis (TB) vaccine since its development in 1921. BCG induces robust T helper 1 (Th1) immune responses but, for many individuals, this is not sufficient for host resistance against Mycobacterium tuberculosis (M. tb) infection. Here we provide evidence that early secreted antigenic target protein 6 (ESAT-6), expressed by the virulent M. tb strain H37Rv but not by BCG, promotes vaccine-enhancing Th17 cell responses. These activities of ESAT-6 were dependent on TLR-2/MyD88 signalling and involved IL-6 and TGF-β production by dendritic cells. Thus, animals that were previously infected with H37Rv or recombinant BCG containing the RD1 region (BCG::RD1) exhibited improved protection upon re-challenge with virulent H37Rv compared with mice previously infected with BCG or RD1-deficient H37Rv (H37RvΔRD1). However, TLR-2 knockout (TLR-2-/-) animals neither showed Th17 responses nor exhibited improved protection in response to immunization with H37Rv. Furthermore, H37Rv and BCG::RD1 infection had little effect on the expression of the anti-inflammatory microRNA-146a (miR146a) in dendritic cells (DCs), whereas BCG and H37RvΔRD1 profoundly induced its expression in DCs. Consistent with these findings, ESAT-6 had no effect on miR146a expression in uninfected DCs, but dramatically inhibited its upregulation in BCG-infected or LPS-treated DCs. Collectively, our findings indicate that, in addition to Th1 immunity induced by BCG, RD1/ESAT-6-induced Th17 immune responses are essential for optimal vaccine efficacy

Profil des patients porteurs d’un cancer bronchique non à petites cellules avancé présentant un contrôle prolongé sous immunothérapie : résultats de la cohorte BREATH

National audienc

Sécurité et efficacité de l’immunothérapie selon un schéma double dose dans le CBNPC avancé : étude rétrospective multicentrique IDEE

National audienceAu cours de la pandémie COVID-19, l’utilisation du pembrolizumab à 400 mg toutes les 6 semaines et Nivolumab 480 4 a été proposée pour limiter venues patients porteurs d’un CBNPC avancé. Cette proposition reposait uniquement sur des données pharmacocinétique pharmacodynamie compatible. L’étude IDEE objectif principal déterminer sécurité l’efficacité ce schéma thérapeutique en condition vie réelle. Nous avons réalisé une étude observationnelle, rétrospective, multicentrique dans centres hospitaliers bretons. Tous atteints avancé ayant reçu au moins dose adaptée entre le 1er mars 2020 2021 ont inclus l’étude. Le suivi effectué jusqu’en 2022. Les cliniques recueillies partir dossiers médicaux. Quatre-vingt-onze l’étude (38 nivolumab semaines, 53 semaines). L’âge médian l’inclusion était 68 ans. La plupart avaient un stade IV (n = 7

BCG induces protection against Mycobacterium tuberculosis infection in the Wistar rat model36573

Our understanding of the correlation of Mycobacterium bovis Bacille Calmette-Guerin (BCG)-mediated immune responses and protection against Mycobacterium tuberculosis (Mtb) infection is still limited. We have recently characterized a Wistar rat model of experimental tuberculosis (TB). In the present study, we evaluated the efficacy of BCG vaccination in this model. Upon Mtb challenge, BCG vaccinated rats controlled growth of the bacilli earlier than unvaccinated rats. Histopathology analysis of infected lungs demonstrated a reduced number of granulomatous lesions and lower parenchymal inflammation in vaccinated animals. Vaccine-mediated protection correlated with the rapid accumulation of antigen specific CD4(+) and CD8(+) T cells in the infected lungs. Immunohistochemistry further revealed higher number of CD8(+) cells in the pulmonary granulomas of vaccinated animals. Evaluation of pulmonary immune responses in vaccinated and Mtb infected rats by real time PCR at day 15 post-challenge showed reduced expression of genes responsible for negative regulation of Th1 immune responses. Thus, early protection observed in BCG vaccinated rats correlated with a similarly timed shift of immunity towards the Th1 type response. Our data support the importance of (i) the Th1-Th2 balance in the control of mycobacterial infection and (ii) the value of the Wistar rats in understanding the biology of TB</p